<DOC>
	<DOCNO>NCT01831089</DOCNO>
	<brief_summary>Clinical trial PM01183 combination paclitaxel , without bevacizumab , patient solid tumor</brief_summary>
	<brief_title>Phase I Study Lurbinectedin ( PM01183 ) Combination With Paclitaxel , With Without Bevacizumab , Selected Advanced Solid Tumors</brief_title>
	<detailed_description>Clinical trial determine maximum tolerate dose ( MTD ) recommend dose ( RD ) PM01183 combination weekly paclitaxel , without bevacizumab . Once recommend dose define PM01183 weekly paclitaxel combination , feasibility add bevacizumab combination explore select cohort patient characterize safety profile feasibility combination , obtain preliminary information antitumor activity , obtain preliminary information quality life ( QoL ) , characterize pharmacokinetics ( PK ) combination detect major drug-drug PK interaction PK/PD ( pharmacokinetic/pharmacodynamic ) correlation conduct exploratory pharmacogenomic ( PGx ) analysis patient select advanced solid tumor .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Voluntarily sign date write informed consent Age 18 75 year old ( inclusive ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 1 Life expectancy ≥ 3 month . Patients histologically/cytologically confirm diagnosis advance and/or unresectable disease follow tumor : 1 . Breast cancer 2 . Epithelial ovarian cancer gynecological cancer 3 . Head neck squamous cell carcinoma 4 . Nonsmall cell lung cancer 5 . Small cell lung cancer 6 . Platinumrefractory germcell tumor . 7 . Adenocarcinoma carcinoma unknown primary site Adequate bone marrow , renal , hepatic , metabolic function Recovery grade ≤ 1 baseline AE derive previous treatment ( exclude alopecia grade ) . Premenopausal woman must negative pregnancy test study entry agree use medically acceptable method contraception throughout treatment period least six week treatment discontinuation Prior treatment PM01183 weekly paclitaxel nanoalbuminpaclitaxel Patients previously discontinue paclitaxelbased regime due drug relate toxicity . Known hypersensitivity bevacizumab component formulation Patients previously discontinue bevacizumabcontaining regime due drugrelated toxicity . More three prior line chemotherapy Less three month since last taxanecontaining therapy . Washout period : 1 . Less three week since last chemotherapycontaining regimen 2 . Less three week since last radiotherapy dose 3 . Less four week since last monoclonal antibodycontaining therapy Concomitant diseases/conditions : Unstable angina , myocardial infarction , valvular heart disease , encephalopathy , ischemic attack , hemorrhagic ischemic cerebrovascular accident ( CVA ) ongoing pulmonary embolism within last year , arrhythmia , hepatopathy , uncontrolled infection , hemoptysis oxygen require dyspnea , know HIV infection , bleed risk , muscular problem , peripheral neuropathy , Symptomatic progressive brain metastasis leptomeningeal disease . Men premenopausal woman use effective method contraception previously describe ; actively breast feed woman . Patients pelvic irradiation dose ≥ 45 Grays ( Gy ) . History previous bone marrow and/or stem cell transplantation . Confirmed bone marrow involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>